Literature DB >> 6446379

Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.

J C Hengst, M B Mokyr, S Dray.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6446379

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  28 in total

1.  Combination chemo-immunotherapy: kinetics of in vivo and in vitro generation of natural killer cells and lymphokine-activated killer cells in the rat.

Authors:  L S Stewart; H F Sewell; A W Thomson
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

2.  Effect of chemotherapy on NK function in the peripheral blood of cancer patients.

Authors:  D P Braun; J E Harris
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.

Authors:  M Hosokawa; Y Sawamura; T Morikage; F Okada; Z Y Xu; K Morikawa; K Itoh; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  Combination chemoimmunotherapy for advanced gastric carcinoma.

Authors:  T Akiyoshi; M Kawaguchi; S Arinaga; S Miyazaki; F Koba; T Wada; H Tsuji
Journal:  Jpn J Surg       Date:  1984-05

Review 5.  The role of tregs in glioma-mediated immunosuppression: potential target for intervention.

Authors:  William Humphries; Jun Wei; John H Sampson; Amy B Heimberger
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

6.  Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.

Authors:  S Ben-Efraim; R C Bocian; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

7.  Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.

Authors:  E Barker; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  Enhanced expansion of the thymic CD8+ cell subset as a potential mechanism for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers.

Authors:  M M Bartik; B A Baumgartel-Scofield; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

9.  Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.

Authors:  L M Weiskirch; E Barker; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

10.  Interference of anti-tumor and immunosuppressive effects of cyclophosphamide in tumor-bearing rats. Analysis of factors determining resistance or susceptibility to a subsequent tumor challenge.

Authors:  D Vidović; M Marusić; F Culo
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.